Literature DB >> 22847790

Outcomes of immunological interventions for mixed chimerism following allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.

Jiro Inagaki1, Reiji Fukano, Takuro Nishikawa, Kentaro Nakashima, Daisuke Sawa, Nobuhiro Ito, Jun Okamura.   

Abstract

BACKGROUND: For children with juvenile myelomonocytic leukemia (JMML) who undergo stem cell transplantation (SCT), the role of immunological interventions including withdrawal of immunosuppressive therapy (IST) and donor lymphocyte infusion (DLI) for treatment of disease recurrence remains uncertain. PROCEDURE: We analyzed serial chimerism status following SCT and evaluated the efficacy of immunological interventions for the management of mixed chimerism (MC) in children with JMML.
RESULTS: Chimerism analysis was available in 26 SCT cases following the first and second SCT. MC was observed in 16 cases and withdrawal of IST was performed in 14 cases immediately after identification of MC. Donor lymphocyte infusion (DLI) was performed in five MC cases. Eight MC cases were observed at the time of neutrophil recovery. Following withdrawal of IST, three cases achieved complete chimerism (CC) while the proportion of autologous cells increased rapidly in the remaining five cases. Six MC cases were observed after achievement of hematological remission (HR) and responses to withdrawal of IST were observed in two cases. In the remaining four cases, despite withdrawal of IST, the proportion of autologous cells increased. Five cases received DLI but only one case responded.
CONCLUSION: Although the benefits of immunological interventions for MC after SCT in JMML were limited, some patients did achieve HR as a result of these treatment modalities without a second SCT. Close monitoring of donor chimerism and early detection of MC is helpful in guiding treatment after SCT in children with JMML.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22847790     DOI: 10.1002/pbc.24259

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  11 in total

1.  Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.

Authors:  Christopher C Dvorak; Prakash Satwani; Elliot Stieglitz; Mitchell S Cairo; Ha Dang; Qinglin Pei; Yun Gao; Donna Wall; Tali Mazor; Adam B Olshen; Joel S Parker; Samir Kahwash; Betsy Hirsch; Susana Raimondi; Neil Patel; Micah Skeens; Todd Cooper; Parinda A Mehta; Stephan A Grupp; Mignon L Loh
Journal:  Pediatr Blood Cancer       Date:  2018-03-12       Impact factor: 3.167

2.  Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.

Authors:  Miharu Yabe; Yoshitoshi Ohtsuka; Kenichiro Watanabe; Jiro Inagaki; Nao Yoshida; Kazuo Sakashita; Harumi Kakuda; Hiromasa Yabe; Hidemitsu Kurosawa; Kazuko Kudo; Atsushi Manabe
Journal:  Int J Hematol       Date:  2014-12-11       Impact factor: 2.490

3.  Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.

Authors:  Hemalatha G Rangarajan; Marcelo S F Pereira; Ruta Brazauskas; Andrew St Martin; Ashleigh Kussman; Ezgi Elmas; Michael R Verneris; Shahinaz M Gadalla; Steven G E Marsh; Sophie Paczesny; Stephen R Spellman; Stephanie J Lee; Dean A Lee
Journal:  Transplant Cell Ther       Date:  2021-08-15

4.  Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells.

Authors:  Baskar Ramdas; Lisa Deng Yuen; Lakshmi Reddy Palam; Roshini Patel; Santhosh Kumar Pasupuleti; Victoria Jideonwo; Ji Zhang; Callista Maguire; Eric Wong; Rahul Kanumuri; Chujing Zhang; George Sandusky; Rebecca J Chan; Chi Zhang; Elliot Stieglitz; Laura Haneline; Reuben Kapur
Journal:  Mol Ther       Date:  2022-04-20       Impact factor: 12.910

5.  Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study.

Authors:  Franco Locatelli; Alessandro Crotta; Annalisa Ruggeri; Mary Eapen; John E Wagner; Margaret L Macmillan; Marco Zecca; Joanne Kurtzberg; Carmem Bonfim; Ajay Vora; Cristina Díaz de Heredia; Lochie Teague; Jerry Stein; Tracey A O'Brien; Henrique Bittencourt; Adrienne Madureira; Brigitte Strahm; Christina Peters; Charlotte Niemeyer; Eliane Gluckman; Vanderson Rocha
Journal:  Blood       Date:  2013-08-07       Impact factor: 22.113

6.  Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.

Authors:  Gabriela Llaurador; Eileen Nicoletti; Susan E Prockop; Susan Hsu; Kirsten Fuller; Audrey Mauguen; Richard J O'Reilly; Jaap J Boelens; Farid Boulad
Journal:  Transplant Cell Ther       Date:  2021-05-31

Review 7.  Role of CBL Mutations in Cancer and Non-Malignant Phenotype.

Authors:  Davide Leardini; Daria Messelodi; Edoardo Muratore; Francesco Baccelli; Salvatore N Bertuccio; Laura Anselmi; Andrea Pession; Riccardo Masetti
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

Review 8.  Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation.

Authors:  Christopher C Dvorak; Mignon L Loh
Journal:  Front Pediatr       Date:  2014-03-28       Impact factor: 3.418

9.  Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.

Authors:  Sachit A Patel; Don W Coulter; Alfred C Grovas; Bruce G Gordon; James L Harper; Phyllis I Warkentin; James L Wisecarver; Warren G Sanger; Peter F Coccia
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

10.  Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.

Authors:  Astrid Wintering; Christopher C Dvorak; Elliot Stieglitz; Mignon L Loh
Journal:  Blood Adv       Date:  2021-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.